Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening disease. It causes scarring of the connective tissue between the functional ...

Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients with idiopathic pulmonary fibrosis in Korea. Recently, the number of patients ...

Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the scarring of their lung tissue is already advanced, and current treatments offer little more ...

Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...

A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...